Urogen Pharma Ltd URGN.OQ, URGN.O is expected to show a rise in quarterly revenue when it reports results on November 6 for the period ending September 30 2025
The Ra'anana Israel-based company is expected to report a 31.3% increase in revenue to $33.093 million from $25.2 million a year ago, according to the mean estimate from 8 analysts, based on LSEG data.
LSEG's mean analyst estimate for Urogen Pharma Ltd is for a loss of 69 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Urogen Pharma Ltd is $33.50, about 38.4% above its last closing price of $20.62
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -0.84 | -0.83 | -1.05 | Missed | -25.9 |
Mar. 31 2025 | -0.81 | -0.80 | -0.92 | Missed | -15 |
Dec. 31 2024 | -0.61 | -0.72 | -0.80 | Missed | -11.1 |
Sep. 30 2024 | -0.81 | -0.82 | -0.55 | Beat | 32.7 |
Jun. 30 2024 | -0.82 | -0.83 | -0.91 | Missed | -9.4 |
Mar. 31 2024 | -0.86 | -0.87 | -0.97 | Missed | -12 |
Dec. 31 2023 | -0.65 | -0.68 | -0.72 | Missed | -5.9 |
Sep. 30 2023 | -0.84 | -0.85 | -0.68 | Beat | 19.6 |
This summary was machine generated November 4 at 15:09 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments